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1ABSTRACT: Genetic testing, currently a diagnostic tool used by only a small fraction
of the population, promises to become a routine and critical part of medical care and drug
prescription in the near future. This change will come chieﬂy through improvements in phar-
macogenomics, the use of genetic testing to tailor medical care to an individual’s unique
genetic makeup. Current regulation of genetic testing is inadequate to meet the challenges
of this new regime. Federal regulatory agencies, and in particular the FDA, are currently
unprepared for the dramatic increase in scope and complexity of both the prescription drug
market and the genetic testing market that is likely to result from the rise of pharma-
cogenomics. Although government advisory committees and legal scholars have long called
for reform of genetic testing regulation, they have focused excessively on the moral dilem-
mas raised by predictive genetic testing at the expense of the increasingly signiﬁcant area
of pharmacogenomic research. This article provides a brief description of genetic testing,
pharmacogenomics, and the current regulatory system, and highlights several areas where
change is long overdue.
With the announcement in 2000 that several research teams had completed a rough map of the human
genome, widespread use of genetic testing technology in medical practice became an attainable – and perhaps
inevitable – future reality. To the extent that our medical destiny is imprinted on our genes, genetic testing
has the potential to facilitate unprecedented prediction, diagnosis, and treatment of disease. The emergence
of such new possibilities has raised widespread concerns about genetic privacy and discrimination, informed
consent, and lack of suﬃcient regulation, particularly in relation to genetic tests that are designed to predict
future disease. Federal regulation of genetic testing is currently incomplete – the FDA and other related
agencies have yet to provide adequate regulatory oversight for the growing genetic testing ﬁeld.
This article argues that an excessive focus on the admittedly serious ethical and policy implications of
predictive genetic testing by government agencies, expert panels, legal academia, and the public has impeded
recognition of the signiﬁcance of pharmacogenomics, a form of genetic testing that promises to bring about
widespread and revolutionary changes to routine medical care. Federal agencies that regulate laboratory
testing and medical devices, most crucially the FDA, must focus on preparing the medical system for the
future central role of pharmacogenomics in the process of testing, prescription, and delivery of drugs.
Part I of this article provides an overview of genetic testing generally and pharmacogenomics in particular.
2Part II lays out the current state of federal regulation of genetic testing. Part III describes recent attempts,
largely through government sponsored advisory groups, to improve federal oversight of genetic testing. Part
IV suggests that although the advice put forth by such advisory groups and by legal academics is important,
it is excessively focused on preventive genetic testing and places insuﬃcient emphasis on pharmacogenomic
genetic testing.
Part I: Genetic Testing and Pharmacogenomics
Genetic testing involves the analysis of DNA, RNA, chromosomes, or certain gene products to detect her-
itable, disease-related DNA alterations.1 Genetics-based molecular testing has been available for approxi-
mately a decade,2 and can currently be used to test for over 900 diseases, including disorders as disparate as
Alzheimer’s disease and colorectal cancer.3 The number of genetic tests performed is expected to continue
to increase dramatically each year.4
Genetic testing may be used for a variety of purposes. Diagnostic testing conﬁrms or rules out a particular
diagnosis in a symptomatic patient; predictive testing determines whether a relevant genetic mutation is
present in an asymptomatic individual; carrier testing determines whether an asymptomatic individual
carries a particular recessive genetic mutation; prenatal testing is used during pregnancy to determine the
health of the fetus; pre-implantation testing is used to test embryos produced through in vitro fertilization,
1Task Force on Genetic Testing, Nat’l Inst. Of Health – Dept. of Energy, Final Report: Promoting Safe and Eﬀective Genetic
Testing in the United States (Sept. 1997), available at <http://www.nhgri.nih.gov/ELSI/TFGT ﬁnal/index.html> [hereinafter
“Task Force Report”].
2Cindy Coty, Delays on the Road to Genetic-Based Testing; Why So Many Diagnostic Tests Have Stalled in the Lab En
Route to the Medical Clinic, Genomics and Proteonomics at 51 (Oct. 1, 2002).
3Genetests (a genetics information resource funded by NIH, HRSA and DOE), available at <http://www.genetests.org>
(last visited February 20, 2003). [hereinafter “Genetests”]; Anny Huang, FDA Regulation of Genetic Testing: Institutional
Reluctance and Public Guardianship, 53 Food & Drug L. J. 555, 558 (1998).
4GartnerG2 Says Physicians Should Prepare to Partner with Genetic Consultants as Genetic Testing Begins to Emerge,
Business Wire (June 18, 2002).
3to reduce the risk of the fetus having a particular genetic condition; and newborn screening is performed
routinely at birth, often mandated by the state.5
Each use raises distinct practical, legal and ethical issues. The most controversial use and that which has
generated the most literature, however, is predictive testing. Critics contend that predictive testing may be
unreliable, and they point to the lack of treatment for many diagnosed diseases for which genetic testing is
or will soon be possible, as well as to the potential for genetic discrimination.
Genetic mutations are the cause of about 3000 to 4000 disorders, and some of these, including Huntington’s
disease, sickle-cell anemia, and cystic ﬁbrosis, are linked to mutations in a single gene.6 For many such
diseases, genetic diagnosis is now common, but ﬁnding or failing to ﬁnd a disease-related genetic variation
is not always conclusive, because some genetic variations in disease-related genes may be benign. The gene
linked to cystic ﬁbrosis, for example, can contain any of over 300 diﬀerent mutations – some of these do
not appear to be related to disease, while others are linked to varying degrees of disease.7 In such cases, a
positive genetic test does not necessarily mean that the subject will develop the disease, while a negative
test can be equally unclear, since the tests screen only for the most common mutations.8
Most diseases cannot be linked to a single gene, but are instead linked to a mix of causes that may include
carcinogens, diet, environment, and genetic mutations. The relationship among these causes is not well-
understood.9 Even when an inherited gene has caused numerous cases of disease within a family (as often
occurs with breast-cancer related genetic mutations, for example), some carriers may remain healthy, perhaps
due to lack of some environmental factor – genes may, for example, be switched on by sunlight.10 The result
5Genetests, supra note 3.
6Notices, Department Of Health And Human Services, Secretary’s Advisory Committee on Genetic Testing, 64 Federal
Register 67273, 67275 (Dec. 1, 1999).
7Access Excellence at the National Health Museum Resource Center, Understanding Gene Testing; What are the limitations
of gene testing? Available at <http://www.accessexcellence.org/AE/AEPC/NIH/gene19.html> (last visited February 21, 2003)
[hereinafter “Access Excellence”].
8Access Excellence, supra note 7.
9Notices, 64 Federal Register at 67275, supra note 6.
10Access Excellence, supra note 7.
4of such uncertainty is that genetic testing cannot reliably predict future disease or the lack of it. Those
receiving the results of a genetic test may not learn of or understand the probabilities associated with the
data, and may either take drastic preventive steps or become dangerously complacent about their chances
of developing a disease. The risk of inadequate consumer information has become especially great with
the advent of direct-to-consumer advertisements for genetic testing, which often inaccurately imply that
particular genetic tests will produce conclusive results.11
Genetic testing for incurable diseases raises particularly troubling questions. When a genetic test for an
incurable disease cannot provide a conclusive result, individuals who test positive for a relevant mutation
must deal with perhaps unwarranted fear. In the case of incurable diseases that may be diagnosed conclusively
through genetic testing (such as Huntington’s disease), those at risk must decide whether they want to know
if they carry the gene, and once they ﬁnd out, they may live many healthy years fearing their future decline.
The specter of widespread predictive testing of this kind has led many to call for signiﬁcant expansion of
genetic counseling services and concerted study of the ethical implications of such testing.12
Discrimination in insurance, employment and other contexts is another danger associated with predictive
genetic testing. Instances of such discrimination have already been reported,13 and promise to become
more common as researchers learn more about genetic links to disease and become better at predicting
future disease long before symptoms appear. About half the states in the United States currently have some
11One recent playbill advertisement for a BRCA breast cancer predictive genetic test, for example, showed a woman covering
her breast, and stated “There is no stronger antidote for fear than information.” It also stated that information “could provide
hope. And dispel fear.” Sandra Gollust, Sara Hull, Benjamin Wilfond, Limitations of Direct-to-Consumer Advertising for
Clinical Genetic Testing, 288 JAMA 1762, 1763 (2002).
12See, e.g., Task Force Report, supra note 1; NIH Report, Enhancing the Oversight of Genetic Tests: Recommendations of
the SACGT (2000) [Hereinafter “SACGT Report”].
13See, e.g., Jennifer Krumm, Genetic Discrimination: Why Congress Must Ban Genetic Testing in the Workplace, 23 J.
Legal Med. 491, 492 (2002) (describing recent cases of genetic discrimination, including one in which a man was refused a
government job because his brother had Gaucher’s disease, and another in which a woman was ﬁred after she disclosed that
she was at risk for developing Huntington’s disease.)
5legislation prohibiting genetic discrimination in the workplace,14 and the federal Health Insurance Portability
and Accountability Act of 1996 (HIPAA) prohibits the use of genetic information without a diagnosis of the
actual condition.15 Many commentators ﬁnd these protections weak and under-inclusive, however, and call
for much more expansive legislation to prevent discrimination on the basis of genetic information.16
Pharmacogenetics and Pharmacogenomics
“Pharmacogenetics” is the study of how genetic diﬀerences among individuals correspond to variability in
drug response. Researchers track such diﬀerences by identifying “single nucleotide polymorphisms” (SNPs),
single base pair alterations in the normal human genetic sequence found in small percentages of the popula-
tion.17 (Variant genetic sequences are labeled “polymorphisms” if they are found in more than one percent
of the population).18 These variations, especially those aﬀecting pharmacokinetics (drug absorption, dis-
tribution, metabolism, and excretion), can signiﬁcantly alter drug eﬀectiveness or increase side eﬀects in
individuals carrying them.19 Detailed pharmacogenetic research has been advanced by the recent develop-
ment of DNA chips – silicon chips embedded with large numbers of distinct bits of DNA. DNA chips could
allow large-scale screening to be performed quickly, either to search for thousands of SNPs in one individual’s
genes, or to study the gene expression of thousands of individuals who share a particular disorder, in order
to determine whether they share a particular SNP.20 There is evidence, for example, that some of the variant
14Robert Curley, Jr. & Lisa Caperna, The Brave New World is Here: Privacy Issues and the Human Genome Project, 70
Def. Couns. J. 22, 32 (2003).
15Curley & Caperna, supra note 14, at 29.
16See, e.g., Curley & Caperna, supra note 14; Krumm, supra note 13; Michael Stein & Anita Silvers, An Equality Paradigm
for Preventing Genetic Discrimination¸55 V. and L. Rev. 1341 (2002); Jared Feldman & Richard Katz, Genetic Testing &
Discrimination in Employment: Recommending A Uniform Statutory Approach, 19 Hofstra Lab. & Emp. L.J. 389 (2002);
Jennifer R. Taylor, Mixing the Gene Pool and the Labor Pool: Protecting Workers from Genetic Discrimination in Employment¸
20 Temp. Envtl. L. & Tech. J. 51 (2001).
17Lars Noah, The Coming Pharmacogenomics Revolution: Tailoring Drugs to Fit Patients’ Genetic Proﬁles¸43 Jurimetrics
J. 1, 6 (2002).
18Noah, supra note 17, at 6.
19Noah, supra note 17, at 3.
20Michael Malinowski, Law, Policy, and Market Implications of Genetic Proﬁling in Drug Development¸2 Hous. J. Health
L. & Pol’y 31, 40 (2002) (hereinafter “Malinowski I”).
6alleles linked to adverse drug reactions are associated with certain ethnic groups,21 and such experiments
can illuminate these types of connections.
The knowledge about individualized drug response that such new technology will bring promises to lead to a
new, potentially signiﬁcant use of genetic testing. Labeled “pharmacogenomics,” it involves using genetic in-
formation to customize medical treatment to a person’s particular genetic makeup.22 Today’s medicines are
marketed as “one-size-ﬁts-all” for any particular medical problem, despite the fact that individuals can diﬀer
dramatically in their responses to a drug treatment. Variability based on dosage responses, allergic reactions,
and other often hereditary factors leads to side eﬀects that kill 100,000 Americans a year, make 2 million
others seriously ill, 23 and, some estimate, lead to health care costs of up to $100 billion annually.24 Al-
though it is unlikely that tracking SNPs will completely eliminate adverse drug reactions, pharmacogenomics
promises an enormous improvement over the current system, under which doctors guess proper dosages or
drug choice based on generalized adverse reaction and dosage data, and then alter the prescription based
on observable patient reaction. The danger of the current trial-and-error system is particularly great for
children, women, and minority groups, since clinical trials that provide data on side eﬀects and dosage are
usually performed on a sample made up mostly of adult white males, a problem that the FDA has begun to
respond to only in the last decade.25 The danger is also great for America’s elderly, who are reaching ages
not reached by previous generations and thus untested as to dosage and drug reaction.26 Within ﬁve years,
tailored prescriptions may begin to signiﬁcantly diminish such problems, and it may become commonplace
for doctors to rely on genetic testing to aid dosage or drug prescription decisions.27
21Lars Noah, supra note 17, at 9.
22Lars Noah, supra note 17, at 3.
23Rick Weiss, The Promise of Precision Prescriptions; ‘Pharmacogenomics’ Also Raises Issues of Race, Privacy¸Wash. Post
A01 (June 24, 2000) (hereinafter “Weiss I”).
24Malinowski I, supra note 20, at 39.
25Lars Noah, supra note 17, at 12-13.
26Malinowski I, supra note 20, at 39.
27Weiss I, supra note 23.
7Interest in pharmacogenomics has also lead to the development of a new ﬁeld, nutritional genomics (or “nu-
trigenomics”), which may ultimately prove as far-reaching and signiﬁcant as pharmacogenomics. Nutrige-
nomics studies the genetic element of the relationship of food to health, analyzing generally how particular
foods aﬀect health, and more speciﬁcally how genetic makeup aﬀects the way that individuals react to foods.
There may, for example, be genetic reasons that the same food raises blood pressure in one individual but has
no such eﬀect on another. Ultimately, nutrigenomics may allow diet to be tailored to an individual’s genetic
makeup, so that diﬀerent varieties of mass market products can be geared to particular subpopulations –
say, to people with hereditary slow metabolism, or hereditary potential for high cholesterol.28
Both pharmacogenomics and nutrigenomics promise to aﬀect a revolution in medical treatment. The most
signiﬁcant result may be the routinization of genetic testing – once pharmacogenomic and nutrigenomic
methods become widespread, genetic testing will become necessary to obtain a prescription or to be a knowl-
edgeable food consumer, and will thus move from its peripheral role in the current medical establishment to
a central one. The ramiﬁcations of such a change are discussed below.
Part II: Government Regulation of Genetic Testing
Three criteria are generally considered relevant for identifying reliable diagnostic tests: analytical validity,
clinical validity, and clinical utility. 29 Analytical validity refers to whether a test properly measures the
property it is designed to measure; an analytically valid genetic test produces a positive result when the
relevant genetic mutation is present (it thus has “analytical sensitivity”) and a negative result when it is
28See generally Andrew Pollack, New Era of Consumer Genetics Raises Hope and Concerns, N.Y. Times F5 (Oct. 1, 2002).
29See, e.g., SACGT Report, supra note 12, at 15-17; Michael Malinowski & Robin Blatt, Commercialization of Genetic
Testing Services: The FDA, Market Forces, and Biological Tarot Cards, 71 Tul. L. Rev. 1211 (1997) (hereinafter “Malinowski
& Blatt”).
8not (it thus has “analytical speciﬁcity”).30 Clinical validity relates to the predictive value of the test in a
clinical setting – in other words, whether and to what degree a positive result is indicative of a medical
condition.31 Finally, clinical utility is an indicator of whether the test is in fact clinically useful, in the sense
that increasing its use would positively aﬀect treatment outcomes.32 As described below, most genetic tests
are currently monitored only for analytical validity, although a small number are tested for clinical validity
and utility as well.
The FDA has authority to regulate genetic testing technology. Genetic tests are considered “diagnostic”
and are thus medical devices under the Federal Food, Drug, and Cosmetics Act’s 1976 Medical Devices
Amendment (MDA), which grants the FDA authority over, among other things, “in vitro reagent[s], or any
other similar or related article, including any component, part, or accessory, which is... intended for use in
diagnosis of disease or other conditions... .” 21 U.S.C.A. § 321(h). The MDA separates medical devices into
three classes regulated in diﬀering degrees based on the concerns they raise about safety and eﬀectiveness.
21 U.S.C.A. § 360c(a). Although the laboratory procedures required for genetic testing are relatively simple,
most genetic tests are considered Class III devices due to the complexity of the criteria for determining their
eﬀectiveness.33 Class III genetic tests must undergo pre-market approval, a process that requires developers
to submit data to the FDA on their test’s safety and eﬀectiveness before they can oﬀer it for sale, unless
they can demonstrate “substantial equivalence” to a previously approved device.34 This rigorous inspection
involves testing for analytical validity, as well as clinical validity and clinical utility.35
30SACGT Report, supra note 12, at 15.
31Model Act for Genetic Privacy and Control, 88 Iowa L. Rev. 121, 128 (2002).
32SACGT Report, supra note 12, at 16-17.
33Jennifer S. Geetter, Coding for Change: The Power of the Human Genome to Transform the American Health Insurance
System¸28 Am. J.L. & Med. 1, 31(2002).
34Huang, supra note 3, at 588.
35Note, Allen C. Nunnally, Commercialized Genetic Testing: The Role of Corporate Biotechnology in the New Genetic Age¸
9Although the MDA classiﬁcation system appears to require signiﬁcant FDA regulatory oversight of genetic
testing, in reality most genetic testing is only minimally scrutinized due to a regulatory loophole that genetic
testing companies have been quick to use to their advantage. Genetic tests can be oﬀered in two forms. In
the ﬁrst, the test is sold directly to hospitals, laboratories, or other health practitioners as “kits,” which are
regulated as Class III devices. Companies can, however, oﬀer to test the samples in their own laboratories;
in that case, the doctor sends the company a DNA sample, and the company sends back the results – this is
typically called a “home brew.” The FDA considers home brews to be “services,” and thus not within the
MDA regulatory requirements.36 Thus, many genetic tests identical to “kits” escape the Class III pre-market
approval process entirely.
Companies oﬀering home brew genetic testing are not, however, entirely free from oversight. Like all labo-
ratories oﬀering tests for clinical purposes (approximately 175,000 in the United States37), these companies
are regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), which is adminis-
tered by the Centers for Medicare and Medicaid Services (CMS) in partnership with the Centers for Disease
Control (CDC). CLIA requires that every laboratory demonstrate the analytical validity of its tests before of-
fering them as a service to the public, meaning in essence that the laboratory must demonstrate its technical
competence.38 CLIA does not, however, require demonstration of either clinical validity or clinical utility.39
In other words, although home brew genetic tests must accurately identify the genetic property they test
for, this property need not be clinically signiﬁcant. Entirely free from oversight in this regard, companies
8 B.U. J. Sci. & Tech. L. 306, 335 (2002).
36Geetter, supra note 33, at 34.
37See Centers for Medicare and Medicaid Services, <http://www.cms.hhs.gov/clia/> (last visited February 22, 2003).
38Neil Holtzman, Symposium, Legal Liabilities at the Frontier of Genetic Testing, Part I. FDA and the Regulation of Genetic
Tests, 41 Jurimetrics J. 53 (2000).
39Nunnally, supra note 35 at 335.
10can easily exaggerate the importance of their results. Several commentators have noted that CMS personnel
administering CLIA have neither the time nor the training to test for clinical validity or clinical utility, and
argue that as a result, any move to broaden such regulation would likely have to be initiated outside of
CLIA.40
Even on a basic accuracy level, CLIA is considered insuﬃcient by many to regulate genetic testing, in part
because its requirements are not speciﬁcally designed for genetic testing,41 and in part because its scope of
regulation is so wide that details can easily be missed. As one commentator has stated, “CLIA is marred by
reporting deﬁciencies and laboratory inspections that are infrequent and insuﬃcient.”42 In one early 1990s
study, the federal government found that 80 to 84 percent of the general physician oﬃce labs inspected had
problems under CLIA, and eleven percent had serious problems.43 Another study of 245 molecular genetic
testing labs by a group of geneticists at New York’s Mt. Sinai School of Medicine found that 15 percent
of the labs – all under CLIA oversight – scored lower than 70 percent on a quality control test.44 Overall,
a “general lack of regulatory quality control on genetic tests ...raises questions about their fundamental
reliability.”45 Many commentators argue that the FDA should have a central role in regulating both genetic
testing kits and “home brews,” based on the agency’s technical competence, experience, and proven record
regulating genetic tests.46
Although the FDA does not regulate home brews, it asserts authority to do so; the agency has said that it
40Holtzman, supra note 38 at 57.
41See, e.g. Task Force Report, supra note 1; Huang, supra note 3, at 590; Lori Andrews, A Conceptual Framework for
Genetic Policy: Comparing the Medical, Public Health, and Fundamental Rights Models, 79 Wash. U. L.Q. 221, 257 (2001).
42See, e.g., Michael J. Malinowski, Legal Liabilities at the Frontier of Genetic Testing, Part I. Separating Predictive Ge-
netic Testing From Snake Oil: Regulation, Liabilities, And Lost Opportunities ¸41 Jurimetrics J. 23, 42 (2000) (hereinafter
“Malinowski II”) (“CLIA alone is unreliable even as a laboratory quality assurance measure.”); Andrews, supra note 41 at 257.
43See Andrews, supra note 41 at 257.
44See Judy Peres, Genetic Testing Can Save Lives – But Errors Leave Scars, Chic. Trib. C1 (Sept. 26, 1999).
45Malinowski & Blatt, supra note 29, at 1233.
46See, e.g., Malinowski II, supra note 42, at 43; Huang, supra note 3, at 590.
11lacks the resources to engage in such extensive regulation.47 Some critics have suggested that the FDA is
cautious about regulating genetic technology generally, due to the unique ethical ramiﬁcations and practical
challenges associated with the subject matter and the heated political controversies surrounding it. 48 The
agency may also be skittish after much criticism over its previous attempts to impede market entry of testing
technologies, including home HIV test kits and home drug test kits.49
Part III: The Controversy Over Reform
Regardless of the reasons for the FDA’s reluctance to impose uniform regulatory requirements on all genetic
testing technology, the discrepancy between the agency’s strict oversight of test kits and its complete lack
of oversight of home brews has generated calls for change for years.50 On the other hand, the biotechnology
industry has met such recommendations for reform with concerns about the eﬀects increased regulation
would have on the development and proﬁtability of genetic testing.51
This controversy, as well as a more general concern that genetic technology was improving at a rate faster
than law was changing to accommodate it, led in 1997 to the establishment of a “Task Force on Genetic
Testing,” sponsored by the National Institutes of Health (NIH) and the Department of Energy (DOE) and
composed mostly of academics and doctors. The Task Force’s goal was to “review genetic testing in the
47The FDA has indicated that while [c]urrently, FDA is not regulating testing[,] the agency maintains that it has such
authority but lacks the resources to review the technology or make and enforce new regulations for the ﬁeld. F-D-C Reports,
Inc., OncorMed BRCA1 Testing Service Commercialization Enters Second Phase Through New IRB Protocol, The Blue Sheet,
(Jan. 17, 1996); See also SACGT Report, supra note 12, at 10 (“FDA has stated that it has authority, by law, to regulate
such tests, but the agency has elected as a matter of enforcement discretion to not exercise that authority, in part because the
number of such tests is estimated to exceed the agency’s current review capacity.”).
48See, e.g. Geetter, supra note 34, at 32-33; Huang, supra note 3, at 571.
49Huang, supra note 3, at 571-2.
50See, e.g., Malinowski & Blatt, supra note 29; Malinowski II, supra note 42; Holtzman, supra note 38; Huang, supra note 3;
but see Richard Merrill, Symposium: Legal Liabilities at the Frontier of Genetic Testing. Genetic Testing: A Role for FDA?,
41 Jurimetrics J. 63 (2000), arguing that the home brew/test kit distinction may be justiﬁed based on jurisdictional concerns,
lack of FDA expertise, and budgetary limitations.
51See SACGT Report, supra note 12, at 26.
12United States and make recommendations to ensure the development of safe and eﬀective genetic tests.”52
In September of 1997, the Task Force released a detailed ﬁnal report entitled “Promoting Safe and Eﬀective
Genetic Testing in the United States,” in which it expressed the general view that commercialization of
genetic testing was advancing too quickly without suﬃcient legal safeguards. It recommended a focus on
preventing discrimination and on access to information through patient informed consent, education of health
professionals, and widely-available genetic counseling.53 The Task Force also recommended eliminating the
distinction between genetic testing kits and home brews, but did not specify what role the FDA should play
in this new regulatory structure.54
In 1998, partially in response to the Task Force’s recommendations, then-Secretary of Health and Human
Services Donna Shalala chartered the Secretary’s Advisory Committee on Genetic Testing (SACGT).55 The
SACGT, managed by the NIH, had a mandate to “advise the government about all aspects of the development
and use of genetic tests, including the complex medical, ethical, legal, and social issues raised by genetic
testing.”56 SACGT gathered information, including public commentary, in 1999 and 2000, and released a
ﬁnal report in July 2000 – “Enhancing the Oversight of Genetic Tests: Recommendations of the SACGT.”57
In the report, SACGT concluded that “the FDA should be the federal agency responsible for the review,
approval, and labeling of all new genetic tests that have moved beyond the basic research phase,” thus
disapproving, as the Task Force had, of the current two-pronged genetic testing regulatory system.58 The
Committee recommended pre-market review of all genetic tests for analytical validity, clinical validity, and
52Task Force Report, supra note 1.
53Task Force Report, supra note 1; William Allen, Panel Seeks Safeguards for Genetic Tests; Expanding Technology Worries
Group ¸St. Louis Post-Dispatch 9A (October 24, 1997).
54See Huang, supra note 3, at 555.
55See “About Secretary’s Advisory Committee on Genetic Testing,” available at <http://www4.od.nih.gov/oba/sacgt.htm>
(last visited February 28, 2003) [hereinafter “SACGT website].
56See SACGT website, supra note 55.
57See Nunnally, supra note 35, at 335-6.
58See SACGT Report, supra note 12, at 27.
13clinical utility, and advised that this review include a consideration of social consequences as well. It
suggested that the stringency of regulation should vary for diﬀerent genetic tests, based on a categorization
system that might take into account criteria such as “test characteristics, availability of safe and eﬀective
treatments, and the social consequences of a diagnosis or identiﬁcation of risk status.”59 In the report, the
Committee promised to release an addendum describing such a categorization system shortly.60 When the
Addendum was released in September 2001, however, it instead described a process of exploring several
possible categorization systems but agreeing on none, due to perceived under- or over-inclusiveness of the
various proposals.61 The report stated:
After consideration of the public comments and additional discussion, the Committee con-
cluded that fundamental, irresolvable questions had been raised about the feasibility of
categorizing tests for oversight purposes based on a limited set of elements in a simple,
linear fashion.62
The biotechnology industry responded to SACGT’s recommendations with apprehension. As reported by the
SACGT, “a number of individuals from industry and professional organizations expressed concerns about the
impact that additional oversight may have on the development, availability, and accessibility of genetic tests
and expressed strong opposition to an increased role for FDA.”63 On the other hand, earlier empirical data
had indicated that some members of the genetic testing industry favored FDA regulation to improve testing
reliability; one 1995 study found that a majority of companies surveyed (including organizations involved in
genetic testing or a related ﬁeld) agreed that “FDA policies, or lack of policies, hinder the development of
59See SACGT Report, supra note 12, at 21.
60See SACGT Report, supra note 12, at 23.
61See Development of a Classiﬁcation Methodology for Genetic Tests: Conclusions and Recommendations of the Secretary’s
Advisory Committee on Genetic Testing, available at <http://www4.od.nih.gov/oba/sacgt/reports/Addendum ﬁnal.pdf> (last
visited February 28, 2003) [hereinafter “SACGT Addendum”].
63SACGT Report, supra note 12, at 26; see also Nunnally, supra note 35, at 336.
14safe and eﬀective genetic test kits or other products.” A vast majority found that “[s]ome laboratories that
oﬀer genetic testing lack quality assurance programs,” and only a small number agreed with the statement
that CLIA policies “assure the quality of genetic test services.”64
By 2001, FDA reform of its bifurcated genetic testing regulation system was widely thought to be imminent.65
The FDA was feeling pressure both from academic commentators and from expert panels to initiate reform,
and several steps undertaken by the Department of Health and Human Services and the FDA itself appeared
to move in this direction. In a January 19, 2001 letter to the SACGT in response to its report, Secretary
of Health and Human Services Donna Shalala outlined a new oversight plan for genetic testing, which, she
wrote, would be particularly responsive to SACGT’s recommendation that “FDA should be the federal
agency responsible for the review, approval and labeling of all new genetic tests that have moved beyond the
basic research phase.” Under the program, she wrote, “oversight of genetic tests will cover clinical genetic
testing services (so called ‘home brews’) as well as genetic test kits.”66 In the SACGT addendum, the
Committee commented on this progress, and cited the planned changes as an additional reason that SACGT
work had temporarily ceased:
SACGT’s decision to defer further work was also based on signiﬁcant progress made by FDA
to develop an innovative regulatory process for genetic tests. At its February 2001 meeting,
SACGT was briefed about the agency’s plans for pre-market review of genetic tests.67
The FDA’s plans never came to fruition, however – the eﬀort slowed signiﬁcantly after the transition from
the Clinton to the Bush administration, and in September 2002, the new Health and Human Services Sec-
retary, Tommy Thompson, disbanded the SACGT, replacing it with the newly formed Secretary’s Advisory
64See Task Force Report, supra note 1, at Appendix 3; see also Andrews, supra note 41, at 256.
65See, e.g., Nunnally, supra note 35, at 337 (“Recommendations recently made by the [SACGT] indicate that diagnostic
genetic testing will soon fall within the purview of FDA regulation.”; SACGT Addendum, supra note 61, at 7.
66Letter from Donna Shalala, Secretary of Health and Human Services, to Edward McCabe, Chair of the SACGT, on January
19, 2001, available at <http://www4.od.nih.gov/oba/sacgt/McCabe.pdf> (last visited March 12, 2003).
15Committee on Genetics, Health, and Society (SACGHS). The SACGHS has yet to schedule any meetings or
release any substantive documents.68 This change was met with widespread consternation, particularly as
it was part of a substantial reshuﬄing of those scientiﬁc advisory groups perceived to be out of line with the
administration’s thinking.69 As one commentator has noted, while every administration tends to appoint
new committee members,
[w]here this administration is breaking with tradition is in its apparent lack of concern about
how this process is viewed by the broader scientiﬁc community and its seating of lobbyists
and political operatives on such committees.70
The change was thus viewed by many as a political maneuver founded on the administration’s disagreements
with the SACGT and its desire to appease the biotechnology industry, although the administration insisted
that it had no such intention, arguing that such an overhaul is normal during the ﬁrst year of an adminis-
tration.71
Part IV: A Mistaken Approach
In light of the nearly unanimous consensus among experts that current FDA regulation of genetic testing ser-
vices is insuﬃcient and improperly structured, the Bush administration’s sudden elimination of the SACGT
and consequent delay of FDA reform was a mistake, and is likely to delay much-needed progress by many
years. Had the FDA initiated the expected changes, however, some of the most signiﬁcant problems with
the current system would not have been addressed regardless. Any real attempt to meet the coming genetic
testing revolution requires recognition of the new role that such testing will soon play in medical treatment
through pharmacogenomics, a fact that neither the government advisory groups nor academic commentators
68See “Secretary’s Advisory Committee on Genetics, Health, and Society, available at
<http://www4.od.nih.gov/oba/sacghs.htm> (last visited March 6, 2003).
69See, e.g., Rick Weiss, HHS Seeks Science Advice to Match Bush Views, Wash. Post A01 (Sept. 17, 2002) (hereinafter
“Weiss II”) (“The Bush administration has begun a broad restructuring of the scientiﬁc advisory committees that guide federal
policy in areas such as patients’ rights and public health, eliminating some committees that were coming to conclusions at odds
with the president’s views and in other cases replacing members with handpicked choices.”); Jon Carroll, Iraq! Iraq! Pay No
Attention To Other Things! San Fran. Chronicle D12 (Sept. 26, 2002); Kathi E.Hanna, Whose Advice? Expert Committees
Get a Makeover; Capital Report, 32 The Hastings Center Report 13 (November 1, 2002).
71See Weiss II, supra note 69.
16have fully appreciated.
As of today, genetic testing is a largely peripheral issue for the general public. Genetic testing captures the
public imagination due to its potential predictive power and concomitant ethical ramiﬁcations, as well as its
popular association with even more controversial scientiﬁc advances such as stem cell research and human
cloning. The reality of receiving a genetic test as part of medical treatment, however, is foreign to the vast
majority to Americans.
This will soon change. Although predictive testing is the most well-known type of genetic testing today,
it will never, by its nature, impact more than a small percentage of the population. Even as scientiﬁc
understanding of genetic links to disease grow, there will remain only a relatively small number of diseases
that can be predicted to a certainty through genetic testing, and many disorders will remain suﬃciently
unpredictable that a test would be medically uninformative. Pharmacogenomics, on the other hand, is likely
to become universal once it advances far enough to provide reliable information. Many researchers predict
that pharmacogenetic research will lead to the categorization of diseases by genetic trait rather than by
type or body part: there won’t be stomach or breast cancer, but rather cancer with a particular genetic
characteristic, treated with a drug particularly manufactured for that genetically identiﬁed cancer.72 Under
such a system, genetic testing will become a required part of disease diagnosis and drug prescription, since
it will be the only method for determining the unique genetic proﬁle of a particular individual’s disease, and
tailoring a drug to ﬁt that proﬁle. As one commentator has noted, “genetic testing is entering the medical
setting as an accompaniment to drug delivery.”73 The social and legal ramiﬁcations of such a change are
unfathomable.74 The FDA should now view genetic testing not as a distinct diagnostic procedure for which
regulatory funding can be cut when money is tight, but as a part of medical care as critical to patient safety
72See Sharon Begley, Made to Order Medicine, Newsweek 64 (June 25, 2001).
73Malinowski I, supra note 20.
74See Weiss I, supra note 23.
17as any drug that the FDA regulates.
Recognition of this change in the role of genetic testing in medicine must accompany any reform in genetic
testing regulation. The current discussion of genetic testing remains, however, mired in an outdated under-
standing of the real importance of such testing. How should the FDA adapt as the sheer number of genetic
tests performed in the United States skyrockets, and genetic tests become routine? Neither the expert pan-
els that have considered genetic testing nor the academics that study its legal implications have seriously
considered this question.
Expert Panels
Although the mandate of the Task Force on Genetic Testing was very general – “to review genetic testing in
the United States and make recommendations to ensure the development of safe and eﬀective genetic tests” –
its report stated clearly that it was “primarily concerned about predictive uses of genetic tests,”75 implying
that predictive tests present the most signiﬁcant policy questions and require the most expert attention.
Thus, the report emphasized improved regulation of test accuracy generally, but focused on the many ethical
issues that arise in the predictive testing arena speciﬁcally. In stating its “overarching principles,” the Task
Force listed concerns such as informed consent (“It is unacceptable to coerce or intimidate individuals or
families regarding their decision about predictive genetic testing.”), the ethics of testing children for adult-
onset diseases, conﬁdentiality, and discrimination. The report makes no mention of pharmacogenomics, or
of the implications of non-predictive genetic testing in general.76
The SACGT, which had a comparably broad mandate to “advise the Department of Health and Human
Services (DHHS) on the medical, scientiﬁc, ethical, legal, and social issues raised by the development and
75Task Force Report, supra note 1.
76See Task Force Report, supra note 1.
18use of genetic tests,”77 similarly focused on predictive genetic tests because “their potential psychological,
social and economic harm are so signiﬁcant and the potential misuse of such information is so great.”78 Like
the Task Force, SACGT placed great emphasis on the need to improve regulation of genetic testing, but
also on informed consent, genetic counseling and education, and discrimination in employment and health
insurance, all most closely related to predictive genetic testing. The “Background” section of the Report
mentions pharmacogenetics, stating that
Pharmacogenetic tests will provide information about the safety and eﬀectiveness of drug
therapies that will help health professionals determine how an individual is likely to respond
to a medicine before it is prescribed, enabling beneﬁcial drugs to be targeted and reducing
drug reactions.79
This is, however, the only section in which pharmacogenomics is mentioned, and pharmacogenomic genetic
tests apparently do not ﬁgure into any further discussions of genetic testing in the report.
Legal Academia
The ethical and social implications of predictive genetic testing have been a fruitful topic for law review
articles since such testing became a realistic possibility. A superﬁcial search for “genetic testing” on any
database of legal academic literature will bring up an enormous number of articles on genetic discrimination
in employment and insurance,80 a signiﬁcant number on the ethics of disclosing genetic testing results for
incurable diseases, either to the patient or to his or her relatives,81 but a miniscule number that discuss
77SACGT Report, supra note 12, at vi.
78SACGT Report, supra note 12, at 8.
80See, e.g., Curley & Caperna, supra note 14; Krumm, supra note 13; Thomas F. Wieder, Privacy Protection is Needed for
DNA ¸2002 L. Rev. Mich. St. U. Det. C.L. 927 (2002); Stein & Silvers, supra note 16.
81See, e.g., Dianne E. Hoﬀman & Eric A. Wufsberg, Testing Children for Genetic Predispositions: Is It in Their Best
Interests?, 23 J.L. Med. & Ethics 331 (1995); Eric T. Juengst, The Ethics of Prediction: Genetic Risk and the Physician-
Patient Relationship, 1 Genome Sci. & Tech. 30 (1995); Angela Liang, The Argument Against A Physician’s Duty To Warn
For Genetic Diseases: The Conﬂicts Created By Safer v. Estate Of Pack, 1 J. Health Care L. & Pol’y (1998).
19pharmacogenomics in any depth or mention genetic testing in a medical but non-predictive context.82 As of
now, “genetic testing” appears to be synonymous with “predictive genetic testing” in the vast majority of
legal literature on the subject, probably a reﬂection of the general public understanding of the terms.83
The Need for a New Perspective
The implications of such a dearth of expert and academic legal commentary on the burgeoning ﬁeld of
pharmacogenomics are severe. The rise of pharmacogenomics promises to lead to a large number of legal,
practical, and ethical questions, some of which have been raised by commentators in the context of predictive
genetic testing, but others of which have not.
The biggest ﬂaw in the current genetic testing regulatory system, and one which will become increasingly
signiﬁcant as pharmacogenomics gains in importance, is the lack of real regulation of genetic test reliability
and accuracy. Both legal academics and the various expert panels that have considered the current system
of regulation of genetic testing have called for reform in this area with commendable persistence. Their
proposal that genetic tests, like drugs, be fully tested for analytical validity, clinical validity, and clinical
utility before entering the market, and that the FDA regulate all genetic tests, regardless of their form,
should be heeded.84 Though the FDA’s expertise and jurisdiction to decide the many ethical dilemmas
posed by predictive genetic testing is questionable, its ability and authority to regulate the reliability of
82Among the few legal articles that discuss pharmacogenomics in any depth are: Noah, supra note 17; Malinowski I, supra
note 20; Wendell W. Weber, Rationales for Population-Speciﬁc Genetic Research: Pharmacogenetics in Indigenous Peoples,
42 Jurimetrics J. 141 (2002); Carol Freund & Benjamin Wilfond, Emerging Ethical Issues in Pharmacogenomics in Section 15:
Posters and Multi-Media Presentations, 29 J.L. Med. & Ethics 42, 46 (2001).
83This of course excludes non-medicine related testing, such as genetic testing for forensic purposes.
84See, e.g., SACGT Report, supra note 12, at 15.
20genetic testing is clear.
As pharmacogenomics leads to the routine use of genetic tests in conjunction with drug prescription, inac-
curacy in a genetic test could become as life-threatening as a mistake in the drug composition itself; wrong
results could lead to prescription of an inappropriate drug dosage, or of a drug that produces a severe adverse
reaction. This is in stark contrast to predictive genetic tests, in which inaccurate test results may lead to
counter-productive medical decisions in the long term, but do not present an immediate health risk. In
this light, the FDA’s previous unwillingness to reform the home brew/test kit regulatory dichotomy due to
limited funds is incongruous, and the Bush administration’s derailment of the SACGT’s promising eﬀorts to
ﬁx this system is unacceptable. A change of perspective is necessary: genetic tests are no longer peripheral
medical devices secondary in importance to other products within the FDA’s regulatory jurisdiction; they
are as central as drugs themselves, and must be regulated as such.
Beyond general reliability, pharmacogenomic genetic testing raises other concerns for the FDA and other
government regulatory agencies that have yet to be considered by experts and scholars, whose interest has
been overly focused on predictive testing:85
•
85For an excellent summary of many of the potential changes pharmacogenomics is likely to bring about, see generally Noah,
supra note 17, the only article I have found that considers this question in depth.
21Should genetic tests be sold “bundled” with particular drugs, or if not, should
drug labels specify recommended genetic tests? Once drugs are marketed toward a particular
genetic proﬁle, these types of bundling systems will likely follow. Antitrust concerns may be
raised by such arrangements.86 In addition, genetic testing recommendations or requirements
on drug labels would introduce a complex and signiﬁcant new category of labeling language for
the FDA to regulate. Inaccuracy in this regard could have dangerous health consequences.
•
What if, as some experts predict, pharmaceutical companies target large genetically
deﬁned groups for a particular disease, and ignore smaller groups?87 This phenomenon would
be similar to the current “orphan drug” problem (which involves pharmaceutical companies
failing to research drugs for rare diseases, due to a lack of potential proﬁtability), but on a much
larger scale. Such a practice might be particularly problematic as genetic diﬀerences often fall
along racial and ethnic lines, leading to the possibility that fewer drugs for particular diseases
will be available for certain minority groups.88 Some genetically identiﬁed groups may also be
labeled as generally “hard to treat” or “high risk subjects.”89 How should such practices be
regulated?
• Will subjects taking part in clinical tests required for FDA drug approval be required to take phar-
macogenomic genetic tests? Such a change seems inevitable; as drugs are tailored to particular genetic
characteristics, they will have to be tested on clinical subjects with the appropriate genetic proﬁle. What
changes should be made to accommodate this development? New privacy concerns for these test subjects
will certainly arise.90
90Of course, this change will give rise to important beneﬁts as well, even beyond those of pharmacogenomics generally.
Using genetic testing with clinical trials will someday allow those who would have adverse reactions to be eliminated from the
study before it begins, leading to much safer testing procedures. See Scott Brown in The Proper Scope of IP Rights in the
Post-Genomics Era: Symposium on Bioinformatics and Intellectual Property Law¸8 B.U. J. Sci. & Tech. L. 233, 244-45 (2002).
22• If genetic tests will be categorized into separate regulatory groups according to the needed stringency of
oversight, as the SACGT originally suggested, how should this categorization be structured? The SACGT’s
view that “predictive tests require more scrutiny than diagnostic tests,” and that “lower scrutiny would
be needed for tests ...used exclusively to direct clinical management of symptomatic patients”91 should be
reconsidered in light of the factors mentioned in this article. While predictive testing may implicate certain
ethical concerns to a higher degree than pharmacogenomic testing, the likely scope of future pharmacoge-
nomic genetic testing and its medical importance argue for extremely strict regulation. The complexity of
categorizing tests with such varied purposes will present a signiﬁcant challenge for government regulators,
the seriousness of which may not have been fully realized due to lack of consideration of pharmacogenomic
genetic tests.
• More generally, pharmacogenomics is likely to greatly increase the complexity of the FDA’s work in
regulating prescription drugs and genetic tests. As drugs are customized, the number of drugs is likely
to skyrocket, with each drug sold to much smaller populations. Stewarding such a large number of drugs
through the approval system is likely to be a momentous task for the FDA, particularly with the added
complexities of testing and labeling mentioned above. In addition, if genetic testing becomes a prerequisite
of receiving a drug prescription, the universalization of genetic testing that will result could raise some of the
same ethical and legal issues often discussed in the context of predictive testing, but on a much wider scale.
For example, certain pharmacogenomic markers are likely to be associated with predictive and diagnostic
genetic markers – in such cases, genetic discrimination and informed consent would be signiﬁcant concerns.92
Pharmacogenomics is a relatively new ﬁeld, as yet adapted to clinical use only on a very small scale. It
is perhaps to be expected that government agencies react to scientiﬁc changes as they arise and regulate
based on the current state of aﬀairs. Such a strategy is, however, inappropriate in the current genetic testing
context, in which drastic and widespread changes are likely to occur in a very short time, a fact that the
agencies themselves and the advisors and scholars who comment on their work have often failed to recognize.
As one commentator has said: “The sooner that federal regulators, the courts, and other policymakers begin
to appreciate the possibilities created by pharmacogenomic research, the more thoughtfully they can address
the challenges presented by this exciting new technology.”93 The ethical quandaries presented by predictive
genetic testing are certainly critical to resolve, but their philosophical appeal should not eclipse the practical
91SACGT Report, supra note 12, at viii.
92Noah, supra note 17, at 22.
93Noah, supra note 17, at 28.
23and legal problems posed by pharmacogenomic research.
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